Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/16/2025 | $51.00 | Overweight | Morgan Stanley |
6/3/2024 | $28.00 | Buy → Neutral | UBS |
6/14/2022 | $47.00 | Buy | UBS |
5/13/2022 | $53.00 | Sector Outperform | Scotiabank |
4/27/2022 | $56.00 | Buy | Goldman |
4/14/2022 | $50.00 | Neutral → Overweight | JP Morgan |
4/6/2022 | $48.00 | Overweight | Morgan Stanley |
10/29/2021 | $50.00 | Neutral → Buy | Citigroup |
4 - Royalty Pharma plc (0001802768) (Issuer)
4 - Royalty Pharma plc (0001802768) (Issuer)
4 - Royalty Pharma plc (0001802768) (Issuer)
SCHEDULE 13G/A - Royalty Pharma plc (0001802768) (Subject)
8-K - Royalty Pharma plc (0001802768) (Filer)
SCHEDULE 13G - Royalty Pharma plc (0001802768) (Subject)
Morgan Stanley initiated coverage of Royalty Pharma with a rating of Overweight and set a new price target of $51.00
UBS downgraded Royalty Pharma from Buy to Neutral and set a new price target of $28.00
UBS resumed coverage of Royalty Pharma with a rating of Buy and set a new price target of $47.00
First of its kind report offers insight from over 110 biopharma executives into the benefits of royalties, current market dynamics and outlook for royalty market expansionRoyalties have become integral to biopharma's diversified capital landscape driven by attractive cost of capital, flexibility and positive investor perception NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the release of a biopharma royalty market study conducted by Deloitte. The report, titled "Role of Royalties in Funding Biopharma Innovation," is the first of its kind and offers a comprehensive analysis of the current dynamics, growth drivers and outlook for biopharma roy
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:20 p.m. ET. The webcast will be accessible from Royalty Pharma's "Events" page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals a
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the "Notes"): $600 million of 4.450% Notes due 2031 (the "2031 Notes");$900 million of 5.200% Notes due 2035 (the "2035 Notes"); and$500 million of 5.950% Notes due 2055 (the "2055 Notes"). The Notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd and Royalty Pharma Manager, LLC. The offering is expected to close on September 16, 2025, subject to the satisfaction of customary closing conditions. Royalty Pharma intends to use the net proceeds from the
Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90%Underscores Royalty Pharma's commitment to enhanced corporate governance following acquisition of its external manager NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective immediately. Carole Ho is Chief Medical Officer and Head of Development at Denali Therapeutics, a biopharmaceutical company focused on neurodegenerative diseases. Bess Weatherman is a Special Limited Partner of Warburg Pincus LLC, a leading global pr
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Vlad Coric, M.D. to the company's Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. "I am excited to announce that we are strengthening our Board with the appointment of Vlad Coric," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "Vlad's entrepreneurial approach and outstanding leadership skills, hon
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experience, responsible for designing and delivering the firm's Human Resources (HR) agenda, including onboarding, colleague engagement, professional development, compensation and benefits. Previously, Molly held a number of global HR roles of increasing responsibility at QBE Insurance Group, Perpetual Limited and National Australia Bank. Molly received her Bachelor of Arts and Master of Applied Science deg
First of its kind report offers insight from over 110 biopharma executives into the benefits of royalties, current market dynamics and outlook for royalty market expansionRoyalties have become integral to biopharma's diversified capital landscape driven by attractive cost of capital, flexibility and positive investor perception NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the release of a biopharma royalty market study conducted by Deloitte. The report, titled "Role of Royalties in Funding Biopharma Innovation," is the first of its kind and offers a comprehensive analysis of the current dynamics, growth drivers and outlook for biopharma roy
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the "Notes"): $600 million of 4.450% Notes due 2031 (the "2031 Notes");$900 million of 5.200% Notes due 2035 (the "2035 Notes"); and$500 million of 5.950% Notes due 2055 (the "2055 Notes"). The Notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd and Royalty Pharma Manager, LLC. The offering is expected to close on September 16, 2025, subject to the satisfaction of customary closing conditions. Royalty Pharma intends to use the net proceeds from the
Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related DiseaseAdditional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Zenas BioPharma, Inc. (NASDAQ:ZBIO) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab. "We are delighted to partner with Zenas as they develop obexelimab in IgG4-RD and other autoimmune diseases," said Pablo Legorreta, founder and CEO
SC 13G/A - Royalty Pharma plc (0001802768) (Subject)
SC 13D/A - Royalty Pharma plc (0001802768) (Subject)
SC 13G/A - Royalty Pharma plc (0001802768) (Subject)